Novel thrombin and factor Xa inhibitors: Challenges to reversal of their anticoagulation effects

Current Opinion in Hematology

Volumn 20, Issue 6, 2013, Pages 552-557

  Yates, Sean ^a   Sarode, Ravi ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

apixaban; dabigatran; oral anticoagulants; prothrombin complex concentrate; rivaroxaban; warfarin

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; DABIGATRAN ETEXILATE; HEMOSTATIC AGENT; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; TARTARIC ACID; THROMBIN INHIBITOR; WARFARIN;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING TEST; CEREBROVASCULAR ACCIDENT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED PRACTICE; EX VIVO STUDY; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LABORATORY TEST; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PATIENT CARE; PLASMAPHERESIS; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; THROMBOEMBOLISM;

ANTICOAGULANTS; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; CLINICAL TRIALS AS TOPIC; FACTOR XA; HEMORRHAGIC DISORDERS; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDONES; THIOPHENES;

EID: 84885403809     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328365a164     Document Type: Review

References (26)

1. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305.
2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
3. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.
4. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-992.
5. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011; 123:1436-1450.
6. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.
7. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008; 6:820-829.
8. Baglin T, Keeling D, Kitchen S. British Committee for Standards in Haematology. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol 2012; 159:427-429.
9. Garcia D, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost 2013; 11:245-252.
10. Stangier J, Rathgen K, Stähle H, et al. The pharmacokinetics, pharmacody-namics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64:292-303.
11. Baglin T. The role of the laboratory in treatment with new oral anticoagulants. J Thromb Haemost 2013; 11:122-128.
12. Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor-interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103:1116-1127.
13. Levy JH, Faraoni D, Spring JL, et al. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology 2013; 118:1466-1474.
14. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23:138-143.
15. Lindhoff-Last E, Ansell J, Spiro T, Samama MM. Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays. Ann Med 2013; 45:423-429.
16. Douxfils J, Mullier F, Loosen C, et al. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 2012; 130:956-966.
17. Harenberg J, Marx S, Weiss C, et al. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost 2012; 10:1433-1436.
18. Samama MM, Contant G, Spiro TE, et al. Evaluation of the antifactor Xa chromogenic assay for the measurement of rivaroxaban plasma concentra tions using calibrators and controls. Thromb Haemost 2012; 107:379-387.
19. Wong PC, Pinto DJP, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis 2011; 31:478-492.
20. Harinstein LM, Morgan JW, Russo N. Treatment of dabigatran-associated bleeding: case report and review of the literature. J Pharm Pract 2013; 26:264-269.
21. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87 (Suppl 1): S141-S145.
22. Lazo-Langner A, Lang ES, Douketis J. Clinical review: clinical management of new oral anticoagulants-a structured review with emphasis on the reversal of bleeding complications. Crit Care Lond Engl 2013; 17:230.
23. Zhou W, Schwarting S, Illanes S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke J Cereb Circ 2011; 42:3594-3599.
24. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124:1573-1579.
25. Ostermann H, Haertel S, Knaub S, et al. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost 2007; 98:790-797.
26. Marlu R, Hodaj E, Paris A, et al. Effect of nonspecific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108:217-224.